A pharmacodynamic biomarker study of vistusertib (AZD2014), an mTORC1/2 inhibitor, given prior to radical prostatectomy (CANCAP02).
2018
5081Background: The effect of novel drugs can be studied in primary prostate cancer (PC), if given prior to radical prostatectomy (RP). Altered PI3K/AKT/mTOR signalling is associated with aggressiv...
Keywords:
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
0
References
2
Citations
NaN
KQI